Nulliparous Pelvic Organ Prolapse - Management

Context: Prolapse in Nulliparous Women

• Connective tissue disorders - Marfan syndrome, Ehlers-Danlos syndrome, inherent collagen deficiency
• Chronic raised intra-abdominal pressure - obesity, chronic cough, constipation/straining, heavy physical labor
• Spina bifida / congenital pelvic anomalies - absence of a complete pelvic floor (e.g., bladder exstrophy) can produce procidentia even in nulliparous women (Campbell-Walsh Wein Urology)
• Prior pelvic surgery - hysterectomy, previous prolapse repair (rectal prolapse shows a similar pattern - up to 1/3 of female rectal prolapse patients are nulliparous)
• Levator ani dysfunction / neuropathy - pudendal nerve damage from non-obstetric causes
• Hormonal / aging changes - progressive smooth and striated muscle loss with collagen increase in the urogenital diaphragm (Berek & Novak's Gynecology)
• Nulliparous women show the lowest prevalence of prolapse, followed by women who delivered only by cesarean, with vaginally parous women at highest risk (Trutnovsky et al., 2016 - Campbell-Walsh Wein)

Key Principles Before Treatment

1. Symptom threshold drives treatment - prolapse only warrants treatment when symptomatic (typically when it reaches or exceeds the hymen). Stages I-II prolapse in asymptomatic women is essentially normal and should not be treated.
2. Nulliparous women are typically younger - fertility preservation and future pregnancy considerations are often central to management decisions.
3. Identify and address the underlying cause - chronic straining, connective tissue disease, obesity.
4. POP-Q staging guides both communication and choice of intervention.

1. Expectant / Conservative (Asymptomatic Prolapse)

• For asymptomatic or minimally symptomatic stages I-II, observation with reassurance is appropriate.
• Natural history data show that in symptomatic women who declined intervention, 78% showed no change, 19% progressed, and 3% regressed over a median 16-month follow-up (Gilchrist et al., 2013 - Campbell-Walsh Wein).
• Lifestyle modification: weight loss, treat chronic cough, manage constipation, avoid chronic straining.

2. Pelvic Floor Muscle Training (PFMT)

• First-line active intervention for symptomatic stages I-III prolapse (IUGA 2024 guidelines).
• Goals (Berek & Novak's): prevent worsening, decrease symptom severity, increase pelvic floor strength and support, delay or avoid surgery.
• A randomized trial (POPPY Trial, cited in Berek & Novak's) showed individualized PFMT reduced prolapse symptoms at 12 months compared to lifestyle leaflet alone.
• Response rate decreases when prolapse extends beyond the vaginal introitus.
• Biofeedback is a useful adjunct, particularly for posterior compartment prolapse / rectocele with obstructed defecation (56% felt improvement in one study - Berek & Novak's).
• Important in nulliparous women: PFMT is especially relevant because these women often lack obstetric pelvic floor damage and may respond well to muscle retraining.

3. Pessary Management

• Women who wish to avoid or delay surgery
• Those who are not surgical candidates
• Women with future pregnancy plans (surgery is generally deferred until childbearing is complete in nulliparous patients)
• Pregnancy-related prolapse

• Patient examined in lithotomy after voiding
• Size estimated by digital examination; ring forceps used to reduce prolapse
• Patient stands, performs Valsalva and coughs to confirm retention
• Must void with pessary in situ before leaving office
• Index finger should sweep between pessary and vaginal wall when correctly sized

4. Surgical Management

• Symptomatic prolapse failing conservative management
• Prolapse beyond the hymen with significant quality-of-life impact
• Patient preference after shared decision-making

• Mesh complications in young women are more consequential
• Pregnancy after mesh repair or sacrocolpopexy carries unknown long-term risks
• Uterine preservation (hysteropexy over hysterectomy) is favored if the uterus is intact

• Sacrospinous ligament fixation (SSLF) - vaginal, native tissue; good for young women who desire vaginal route; higher recurrence than sacrocolpopexy
• Uterosacral ligament suspension (USLS) - vaginal, native tissue
• Sacrocolpopexy - abdominal/laparoscopic/robotic, mesh augmentation to sacrum; durable long-term results; preferred in younger, active women but mesh considerations apply
• Hysteropexy (uterine-preserving suspension) - increasingly favored when uterus is present; options include sacrospinous hysteropexy and abdominal sacrohysteropexy
• AUGS published a Clinical Practice Statement on Uterine Preservation at POP repair in April 2025

• Anterior colporrhaphy (native tissue plication) - standard vaginal approach
• Paravaginal repair (vaginal or retropubic) - for lateral defect cystocele

• Traditional posterior colporrhaphy (site-specific or midline plication)
• Perineorrhaphy as needed
• Biofeedback adjunct for defecatory symptoms

• Sacrocolpopexy uses permanent mesh - excellent durability but carries FDA-recognized risks (erosion, pain, dyspareunia)
• Transvaginal mesh for anterior/posterior repair has significant controversy and regulatory restriction in many jurisdictions
• In young nulliparous women, the risk-benefit of mesh must be discussed explicitly, particularly given long life expectancy and potential future pregnancies

5. Special Considerations in Nulliparous Women

Summary Algorithm

Nulliparous woman with POP
        ↓
Asymptomatic (stage I-II)?  →  Watchful waiting + lifestyle modification
        ↓ (symptomatic)
PFMT (physiotherapy) ± biofeedback  [1st line]
        ↓ (persistent symptoms / stage III+)
Pessary  ←  preferred if future pregnancy planned or surgery declined
        ↓ (pessary failure or patient prefers surgery; childbearing complete)
Surgery:
  - Uterine preservation preferred (hysteropexy)
  - Apical fixation (USLS or SSLF; sacrocolpopexy in fit patients)
  - Compartment-specific repair
  - Minimize mesh in young women
  - Address all concomitant compartments

• Berek & Novak's Gynecology, pp. 1593-1620 (POP pathophysiology, conservative management, pessary, surgical management)
• Campbell-Walsh-Wein Urology (POP epidemiology, risk factors, natural history)
• IUGA Workshop "How Do We Treat POP in 2024?" (IUGA guidelines)
• AUGS Clinical Practice Statement: Uterine Preservation at POP Repair, April 2025

Recent evidence note: A 2023 Cochrane Review (PMID 37431855) examined oestrogen therapy for POP in postmenopausal women - less directly applicable to the typically pre-menopausal nulliparous patient, but topical estrogen remains important adjunct when using pessaries in any hypoestrogenic state.